Zymeworks to Acquire Theravance Biopharma in a $929 Million Deal
Theravance Biopharma, Inc. (TBPH) entered a merger agreement on June 29, 2026, to be acquired by Zymeworks Inc. (ZYME) in a deal valued at $929 million. Deal Structure: Theravance…
Written byAsif SuriaSource: InsideArbitrage
Theravance Biopharma, Inc. (TBPH) entered a merger agreement on June 29, 2026, to be acquired by Zymeworks Inc. (ZYME) in a deal valued at $929 million. Deal Structure: Theravance Biopharma shareholders will receive $17 in cash, representing a 3.57% discount to the stock’s last close. Theravance Biopharma shareholders will also receive a contingent value right entitling